Sun Pharma announced its Q2 FY26 results, showcasing an 8.6% sales growth, reaching INR144,052 million. The company’s EBITDA increased by 14.9% to INR45,271 million, with a margin of 31.3%. Global Innovative Medicines sales rose by 16.4% to USD313 million. The company continues to invest in R&D, with a focus on innovative medicines and expansion in key markets.
Financial Performance Overview
Sun Pharmaceutical Industries Limited reported strong financial results for Q2 FY26. Key highlights include:
- Sales: INR144,052 million, an increase of 8.6% compared to Q2 FY25.
- Gross Margin: 79.3% for the quarter.
- EBITDA: INR45,271 million, up by 14.9% year-over-year.
- EBITDA Margin: 31.3%.
- Net Profit After Tax: INR31,180 million, a 2.6% increase.
- EPS: INR13 per share.
For the first half of the fiscal year, sales reached INR2,81,913 million, representing a 9.3% growth. The EBITDA for the first half was INR88,287 million, a 17% increase.
Global Innovative Medicines
Global Innovative Medicines sales increased by 16.4% to USD313 million. U.S. sales of Innovative Medicines surpassed generics for the first time this quarter.
India Business
Formulation sales in India were INR47,348 million, representing an 11% growth. India’s Formulation sales accounted for 32.9% of total consolidated sales for the quarter. Sun Pharma holds 8.3% market share in the Indian pharmaceutical market.
U.S. Business
The overall U.S. business declined by 4.1% to $496 million for the quarter. This decline was partially offset by growth in Innovative Medicines.
R&D Investments
Consolidated investments in R&D for Q2 FY26 were INR7,827 million, or 5.4% of sales. Innovative R&D accounted for 38% of the total R&D spend.
The company awaits FDA decision on UNLOXCYT updated labeling and remains on track to launch UNLOXCYT in the U.S. in the second half of FY ’26. Plans are underway to file ILUMYA psoriatic arthritis sBLA during the second half of FY ’26.
Source: BSE
